Gemayel Georges's Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Sep 17, 2024
- Accession no.
- 0001628280-24-040598
- Filed
- Sep 17, 2024
- Trade date
- Sep 13, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $435.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gemayel GeorgesCIK 0001256088 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | Common Stock | SSaleDisposed | −3,886 | $31.33 | −$121,748.38 | 13,315 | Direct | |
| Sep 13, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $11.46 | +$114,600 | 23,315 | Direct | |
| Sep 13, 2024 | Common Stock | SSaleDisposed | −10,000 | $31.33 | −$313,300 | 13,315 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 25,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.